Advancing DILI Assessment Using Micropatterned Co-Culture Models: HEPATOPAC® and HEPATOMUNE® скачать в хорошем качестве

Advancing DILI Assessment Using Micropatterned Co-Culture Models: HEPATOPAC® and HEPATOMUNE®

Drug-induced liver injury (DILI) is a major contributor to clinical trial failures and post-marketing drug withdrawals. Conventional preclinical models often fail to predict hepatotoxicity due to species-specific differences and limited physiological relevance. Human-relevant in vitro platforms, such as HEPATOPAC® and HEPATOMUNE®, offer improved functionality by maintaining long-term hepatocyte activity and incorporating non-parenchymal cells. This presentation highlights a study comparing the hepatotoxic effects of trovafloxacin, a DILI-associated antibiotic, with its non-toxic analog, moxifloxacin. Functional toxicity assays were performed across HEPATOPAC®-based models, with ongoing transcriptomic analysis aimed at uncovering early molecular responses. These models support a more physiologically relevant approach for evaluating DILI risk during drug development. Download the slides or register for the other webinars in the series: https://info.bioivt.com/bioivt-webina... Questions, comments and requests: https://bioivt.com/about/contact-us More information on our research services and test systems: https://bioivt.com/ Other previously aired webinars: https://bioivt.com/educational-conten...) Upcoming webinar notifications: https://bioivt.com/resources/newslett... About the HEPATOPAC Webinar Series Offered as a research service or kit, HEPATOPAC® is a long-term hepatic micropatterned co-culture (MPCC) that has been shown to provide superior data, especially for low turnover compounds, compared to conventional in vitro models. HEPATOPAC has been widely used in metabolism and toxicity studies and is now being adopted for other ADME applications. The goal of providing more accurate preclinical data is the primary driving force behind the NAMs initiative that is a current focal point of regulatory agencies and industry organizations. HEPATOPAC falls under the NAMs category of Microphysiological Systems (MPS). As an established MPS, HEPATOPAC has been included in the new 3Rs Collaborative (3RsC) between regulators, technology providers, end-users, and non-profits to advance the use of MPS in regulatory applications. With the NIH’s recent announcement that they will no longer issue Notices of Funding Opportunities exclusively supporting animal models combined with the potential benefits in the regulatory review process mentioned in the announcements for the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies, the push to utilize validated NAMs is increasing in momentum. This webinar series will evaluate the use of HEPATOPAC for a variety of applications. About the Presenter Sara Geriesh is a Ph.D. student in Pharmaceutical Sciences at the University of Maryland, Baltimore, working in Dr. Hongbing Wang’s lab. She holds a bachelor’s degree in Clinical Pharmacy and a master’s degree in Pharmacology from Georgetown University. Her research focuses on drug-induced liver injury (DILI) and metabolism-based drug-drug interactions using advanced human-relevant liver models. Her current work integrates functional assays and transcriptomic profiling to uncover hepatotoxicity mechanisms and biomarkers, contributing to FDA-funded efforts aimed at improving preclinical drug safety evaluation.